TenNor Therapeutics, a Suzhou, China-based clinical stage company dedicated to developing new therapies for infectious diseases, raised over RMB300M in Series E funding.
Backers included AMR Action Fund, Zhongshan Venture Capital and other existing investors.
The company intends to use the funds to support the development and to seek regulatory approval in China of rifasutenizol, which could become the first new drug developed specifically for Helicobacter pylori infection in more than 30 years.
Led by Dr. Zhenkun Ma, Founder and CEO, TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products against diseases associated with bacterial infection and metabolism. It possesses a multi-targeting drug conjugate technology platform and a strong new drug development portfolio with global IP protection. Several products are currently in late-stage of clinical development targeting H. pylori infection, medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the needs in the disease area and provide safe and effective therapies for patients in China and around the world.
FinSMEs
20/10/2024